SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Hospice and Palliative Medicine®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Nelson, K. A.
Right arrow Articles by Hussein, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, K. A.
Right arrow Articles by Hussein, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A phase II study of low-dose megestrol acetate using twice-daily dosing for anorexia in nonhormonally dependent cancer

Kristine A. Nelson, MD

Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio, Board of Scientific Counselors, Cancer Treatment Research Foundation, Arlington Heights, Illinois

Declan Walsh, MSc, FACP, FRCP (Edin)

Harry R. Horvitz Center for Palliative Medicine, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio

Mohamad Hussein, MD

Multiple Myeloma Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio

Anorexia is a common problem in advanced cancer. Low-dose megestrol acetate, a semi-synthetic progesterone, given twice daily, is an effective appetite stimulant in advanced cancer patients. There was an excellent correlation between patient satisfaction and the primary response criteria (appetite improvement). Given cost, side-effect profile, ease of administration, and efficacy, 80 mg twice daily after meals is an appropriate starting dose of megestrol acetate for anorexia in advanced cancer. If this is not effective, considerable dose escalation is possible.

Key Words: anorexia • cancer • megestrol acetate • symptom management

American Journal of Hospice and Palliative Medicine®, Vol. 19, No. 3, 206-210 (2002)
DOI: 10.1177/104990910201900313
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement